September 30, 2020 -- An investigational antibody cocktail by Regeneron Pharmaceuticals reduced the viral loads and improved the systems of nonhospitalized COVID-19 patients, according to data from its phase I/II/III trial.
REGN-COV2, a combination of two monoclonal antibodies, also had a positive effect in reducing medical visits, according to the ongoing, randomized double-blind trial that aims to measure the benefit of adding REGN-COV2 to the usual standard of care. Of the first 275 patients enrolled, approximately 45% were seropositive and 41% were seronegative. REGN-COV2 reduced viral load through day seven in seronegative patients.
The trial is included in a larger research program that is studying the cocktail for treating hospitalized patients and for preventing infections in those who have been exposed to COVID-19 patients.